Ich stimme zu, dass diese Seite Cookies verwende. Weitere Informationen finden Sie unter unseren Datenschutzerklärungen .
X
Esteva, Francisco
105  Ergebnisse:
OpenAccess-Volltexte X
Personensuche X
?
1

A new paradigm for classifying and treating HER2‐positive b..:

He, Xuexin ; Yeung, Sai‐Ching J ; Esteva, Francisco J
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432420/.  , 2023
Link: http://www.ncbi.nlm.nih...
 
?
2

Safety and impact of dose reductions on efficacy in the ran..:

Burris, Howard A ; Chan, Arlene ; Bardia, Aditya...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8405616/.  , 2021
Link: http://www.ncbi.nlm.nih...
 
?
3

Safety and impact of dose reductions on efficacy in the ran..:

Burris, Howard A ; Chan, Arlene ; Bardia, Aditya...
British Journal of Cancer, Vol.125 No.5, pp.679-686.  , 2021
Link: https://hdl.handle.net/1..
 
?
4

Overall Survival with Ribociclib plus Fulvestrant in Advanc..:

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen...
New England Journal of Medicine, Vol.382 No.6, pp.514-524.  , 2020
Link: https://hdl.handle.net/1..
 
?
5

Validation of plasma metabolites associated with breast can..:

Zhao, Hua ; Shen, Jie ; Ye, Yuanqing...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7710579/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
6

Ribociclib plus fulvestrant for advanced breast cancer: Hea..:

Fasching, Peter A ; Beck, J. Thaddeus ; Chan, Arlene...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567051/.  , 2020
Link: http://www.ncbi.nlm.nih...
 
?
7

Overall Survival with Ribociclib plus Fulvestrant in Advanc..:

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen...
http://hdl.handle.net/10668/14815.  , 2019
Link: http://hdl.handle.net/10..
 
?
8

Phase III randomized study of ribociclib and fulvestrant in..:

Slamon, Dennis J ; Neven, Patrick ; Chia, Stephen...
Journal of Clinical Oncology, Vol.36 No.24, pp.2465-2472.  , 2019
Link: https://hdl.handle.net/1..
 
?
9

Are Biosimilars the Future of Oncology and Haematology?:

Zinzani, Pier Luigi ; Dreyling, Martin ; Gradishar, William...
boreal:225096.  , 2019
Link: http://hdl.handle.net/20..
 
?
10

Are Biosimilars the Future of Oncology and Haematology?:

Zinzani, Pier Luigi ; Dreyling, Martin ; Gradishar, William...
boreal:225096.  , 2019
Link: http://hdl.handle.net/20..
 
?
11

A plasma protein derived TGFβ signature is a prognostic ind..:

Katayama, Hiroyuki ; Tsou, Peiling ; Kobayashi, Makoto...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445093/.  , 2019
Link: http://www.ncbi.nlm.nih...
 
?
12

Trastuzumab resistant HER2+ breast cancer cells retain sens..:

Wielgos, Monica E ; Zhang, Zhuo ; Rajbhandari, Rajani...
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5932278/.  , 2018
Link: http://www.ncbi.nlm.nih...
 
?
13

Expression of human endogenous retrovirus-K is strongly ass..:

Johanning, Gary L ; Malouf, Gabriel G ; Zheng, Xiaofeng...
info:eu-repo/semantics/altIdentifier/doi/10.1038/srep41960.  , 2017
Link: https://hal.sorbonne-uni..
 
?
14

Expression of human endogenous retrovirus-K is strongly ass..:

Johanning, Gary L ; Malouf, Gabriel G ; Zheng, Xiaofeng...
info:eu-repo/semantics/altIdentifier/doi/10.1038/srep41960.  , 2017
Link: https://hal.sorbonne-uni..
 
?
15

In Support of a Patient-Driven Initiative and Petition to L..:

Tefferi, Ayalew ; Kantarjian, Hagop ; Rajkumar, S Vincent...
qt674381fd.  , 2015
Link: https://escholarship.org..
 
1-15